Does Lower Dopamine Transporter Binding After Methamphetamine Use Prove Neuron Loss?

A lower brain-imaging measurement is a finding to interpret, not a direct count of dead neurons. In a historical 1998 study, McCann and colleagues found reduced dopamine transporter binding in small groups with histories of methamphetamine or methcathinone use. The authors considered neurotoxicity a possible explanation while explicitly retaining neuroadaptation as an alternative.

Who was actually studied?

The observational human study included ten controls, six people with a history of methamphetamine use, four with a history of methcathinone use, and three patients with newly diagnosed Parkinson disease. Methcathinone is a separate drug; its four participants should not be added to the methamphetamine group and described as ten methamphetamine participants.

The methamphetamine participants were recruited from rehabilitation groups. Methcathinone participants were identified through drug-enforcement contacts while incarcerated. Both groups reported other recreational drug use as well. Exposure histories came from interviews and questionnaires, including reported amounts, routes and periods of use; investigators did not administer a standardized methamphetamine regimen or retrospectively verify its purity.

Participants reported approximately three years of abstinence on average, with considerable individual variation. Serum and urine immunoassay screens were negative for recent drug use before imaging. Those screens supported the absence of recently detectable exposure under the testing conditions. They could not independently verify every month of the retrospectively reported abstinence period.

What did the PET scan measure?

Investigators administered the radiotracer [¹¹C]WIN-35,428 intravenously and measured its regional behavior over a 90-minute scanning period. The tracer binds dopamine transporters. A compartment model produced binding potential, expressed as the ratio k3/k4, for the caudate nucleus and putamen.

Binding potential is a modeled tracer measurement. It is not a methamphetamine concentration in whole blood, a dopamine concentration, or a histological neuron count. The paper itself notes that binding can reflect properties of transporter availability and ligand binding. A percentage difference in binding cannot simply be renamed the percentage of neurons lost.

How large were the reported differences?

Table 3 gives uncorrected mean binding potentials of 7.5 in the caudate and 7.3 in the putamen for controls, compared with 5.8 and 5.5, respectively, in the six methamphetamine participants. These correspond to the approximately 23% and 25% reductions described in the paper. They are group comparisons, with variation within groups, rather than individual diagnostic thresholds.

Age required attention. The mean ages were 30.5 years for controls, 37.5 for the methamphetamine group and 53.3 for the Parkinson group. The authors analyzed age as a covariate and also applied a separate age-correction procedure. The methamphetamine comparisons remained significant under both approaches. One methcathinone putamen comparison ceased to be significant after the separate correction, an important qualification to any combined “amphetamine users” summary.

Why was Parkinson disease included?

The three Parkinson patients provided a clinical comparison with a condition involving dopaminergic degeneration. They had substantially lower putamen binding than the other groups. The methamphetamine and methcathinone participants did not show clinical parkinsonism on the neurological assessment.

A shared direction of change in an imaging marker does not establish that two groups have the same disease. Nor did the absence of a significant caudate difference between the small Parkinson and drug-history groups establish equivalence. With only three Parkinson patients and six methamphetamine participants, uncertainty is substantial.

Did the study distinguish injury from adaptation?

Not conclusively. The authors favored a possible neurotoxic contribution based partly on prior animal work, but acknowledged that persistent transporter reduction could reflect neuroadaptation without actual terminal degeneration. This human study did not include brain histology or a pre-exposure scan of the same participants.

Selection into the groups, co-use of other drugs, retrospective exposure reports and unmeasured pre-existing differences also limit causal interpretation. A cross-sectional scan after a reported abstinence period can show an association at that examination. It does not demonstrate the participant’s trajectory from a known personal baseline or establish that the observed difference is irreversible.

Can it predict future disease or current impairment?

The authors raised future parkinsonism as a question requiring longitudinal research. The study did not follow these groups to measure an incidence rate or calculate an individual’s future probability of Parkinson disease. That proposed concern must remain distinct from an observed outcome.

Likewise, the PET findings do not establish an individual’s driving impairment, cognitive capacity or cause of a current complaint. A client explanation should preserve the drug-specific groups, the imaging endpoint and the historical uncertainty: lower transporter binding was observed; neuronal death, permanent functional loss and future disease were not directly established by this experiment.

Scientific source

McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [¹¹C]WIN-35,428. Journal of Neuroscience. 1998;18(20):8417–8422. doi:10.1523/JNEUROSCI.18-20-08417.1998. Historical observational human study.